Hemant Varma, M.B.,B.S., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Huntington Disease | 6 | 2010 | 1124 | 0.920 |
Why?
|
| Postmortem Changes | 1 | 2021 | 126 | 0.780 |
Why?
|
| Astrocytoma | 3 | 2023 | 790 | 0.780 |
Why?
|
| SOS1 Protein | 1 | 2020 | 41 | 0.740 |
Why?
|
| Glioma | 4 | 2023 | 3401 | 0.710 |
Why?
|
| Estrogen Receptor Modulators | 3 | 2007 | 61 | 0.710 |
Why?
|
| Spinal Canal | 1 | 2019 | 39 | 0.700 |
Why?
|
| Meningeal Neoplasms | 4 | 2023 | 1241 | 0.690 |
Why?
|
| Mumps | 1 | 2020 | 64 | 0.680 |
Why?
|
| Germinal Center | 1 | 2020 | 377 | 0.620 |
Why?
|
| Meningioma | 3 | 2023 | 1209 | 0.620 |
Why?
|
| Mitochondrial Encephalomyopathies | 1 | 2016 | 37 | 0.570 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2016 | 48 | 0.570 |
Why?
|
| Encephalitis | 1 | 2020 | 423 | 0.550 |
Why?
|
| Glioblastoma | 4 | 2023 | 3481 | 0.510 |
Why?
|
| Liver Failure, Acute | 1 | 2016 | 165 | 0.500 |
Why?
|
| Brain Neoplasms | 8 | 2023 | 8863 | 0.500 |
Why?
|
| Hemangioma | 1 | 2019 | 738 | 0.470 |
Why?
|
| Cathepsin L | 1 | 2013 | 75 | 0.450 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2016 | 486 | 0.450 |
Why?
|
| Hydrocephalus | 1 | 2020 | 748 | 0.450 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2020 | 1381 | 0.450 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2020 | 895 | 0.420 |
Why?
|
| Spinal Neoplasms | 1 | 2019 | 760 | 0.420 |
Why?
|
| DNA, Mitochondrial | 1 | 2016 | 817 | 0.390 |
Why?
|
| Small Molecule Libraries | 3 | 2013 | 720 | 0.380 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 1378 | 0.380 |
Why?
|
| Retinoblastoma Protein | 2 | 2007 | 704 | 0.380 |
Why?
|
| Neurodegenerative Diseases | 2 | 2010 | 1061 | 0.360 |
Why?
|
| Nerve Tissue Proteins | 4 | 2013 | 4462 | 0.340 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2020 | 496 | 0.330 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2010 | 1375 | 0.320 |
Why?
|
| Thiophenes | 1 | 2013 | 588 | 0.320 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2013 | 1086 | 0.310 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2007 | 191 | 0.300 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 4665 | 0.300 |
Why?
|
| Nuclear Proteins | 4 | 2015 | 5853 | 0.280 |
Why?
|
| Multiple Sclerosis | 1 | 2021 | 3079 | 0.280 |
Why?
|
| Isocitrate Dehydrogenase | 3 | 2023 | 871 | 0.280 |
Why?
|
| Brain | 3 | 2021 | 26385 | 0.270 |
Why?
|
| Organic Chemicals | 1 | 2006 | 211 | 0.270 |
Why?
|
| Autophagy | 1 | 2013 | 1300 | 0.250 |
Why?
|
| Microtubules | 1 | 2010 | 1090 | 0.250 |
Why?
|
| Estradiol | 2 | 2002 | 2020 | 0.230 |
Why?
|
| Mutation | 7 | 2023 | 29786 | 0.230 |
Why?
|
| Glycolysis | 1 | 2007 | 827 | 0.230 |
Why?
|
| Cell Death | 4 | 2010 | 1706 | 0.210 |
Why?
|
| Oligodendroglioma | 1 | 2023 | 279 | 0.210 |
Why?
|
| Cytogenetic Analysis | 1 | 2022 | 295 | 0.200 |
Why?
|
| Hyperbilirubinemia | 1 | 2021 | 77 | 0.190 |
Why?
|
| Methylene Blue | 1 | 2021 | 155 | 0.190 |
Why?
|
| Neurons | 3 | 2010 | 9338 | 0.190 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2022 | 169 | 0.190 |
Why?
|
| Ependyma | 1 | 2020 | 54 | 0.180 |
Why?
|
| PC12 Cells | 2 | 2013 | 330 | 0.180 |
Why?
|
| Cerebral Aqueduct | 1 | 2020 | 39 | 0.180 |
Why?
|
| Cytogenetics | 1 | 2020 | 203 | 0.180 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2000 | 258 | 0.180 |
Why?
|
| Mitochondria | 2 | 2016 | 3520 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 3 | 2021 | 6314 | 0.170 |
Why?
|
| Gliosis | 1 | 2020 | 245 | 0.170 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2021 | 379 | 0.170 |
Why?
|
| Pons | 1 | 2020 | 245 | 0.160 |
Why?
|
| Chondroma | 1 | 2018 | 58 | 0.160 |
Why?
|
| Granular Cell Tumor | 1 | 2018 | 51 | 0.160 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2000 | 415 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2019 | 462 | 0.150 |
Why?
|
| Vasoconstrictor Agents | 1 | 2021 | 642 | 0.150 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2022 | 2649 | 0.150 |
Why?
|
| Cerebral Ventricles | 1 | 2020 | 544 | 0.150 |
Why?
|
| Muscular Dystrophy, Oculopharyngeal | 1 | 2016 | 8 | 0.150 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2010 | 625 | 0.140 |
Why?
|
| High-Throughput Screening Assays | 2 | 2013 | 944 | 0.140 |
Why?
|
| Tamoxifen | 1 | 2000 | 981 | 0.130 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2002 | 1524 | 0.130 |
Why?
|
| Ophthalmoplegia | 1 | 2016 | 166 | 0.130 |
Why?
|
| Fatal Outcome | 1 | 2020 | 1850 | 0.130 |
Why?
|
| Thoracic Vertebrae | 1 | 2019 | 608 | 0.120 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2002 | 2015 | 0.120 |
Why?
|
| Cell Culture Techniques | 1 | 2021 | 1678 | 0.120 |
Why?
|
| Humans | 24 | 2023 | 744343 | 0.110 |
Why?
|
| Chromosome Aberrations | 1 | 2020 | 1813 | 0.110 |
Why?
|
| Estrogens | 1 | 2000 | 1566 | 0.110 |
Why?
|
| Apoptosis | 4 | 2021 | 9727 | 0.110 |
Why?
|
| Disease Models, Animal | 3 | 2010 | 18029 | 0.110 |
Why?
|
| Cell Survival | 3 | 2023 | 5882 | 0.110 |
Why?
|
| Middle Aged | 7 | 2021 | 213383 | 0.110 |
Why?
|
| Breast Neoplasms | 3 | 2007 | 20822 | 0.100 |
Why?
|
| Prognosis | 3 | 2021 | 29063 | 0.100 |
Why?
|
| Signal Transduction | 3 | 2010 | 23403 | 0.100 |
Why?
|
| Reactive Oxygen Species | 2 | 2010 | 2077 | 0.100 |
Why?
|
| Gene Deletion | 1 | 2019 | 2751 | 0.100 |
Why?
|
| Male | 9 | 2022 | 350118 | 0.100 |
Why?
|
| Adult | 6 | 2022 | 214055 | 0.090 |
Why?
|
| Parietal Lobe | 1 | 2015 | 838 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 2043 | 0.090 |
Why?
|
| Pituitary Neoplasms | 1 | 2018 | 1345 | 0.090 |
Why?
|
| Rats | 3 | 2013 | 24260 | 0.090 |
Why?
|
| Cyclin D1 | 2 | 2002 | 463 | 0.090 |
Why?
|
| Biopsy | 1 | 2021 | 6756 | 0.090 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2010 | 241 | 0.090 |
Why?
|
| Enzyme Activation | 2 | 2007 | 3701 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2021 | 648 | 0.080 |
Why?
|
| Necrosis | 1 | 2013 | 1643 | 0.080 |
Why?
|
| Cyclin A | 1 | 2007 | 60 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2000 | 3703 | 0.080 |
Why?
|
| Rotenone | 1 | 2007 | 43 | 0.080 |
Why?
|
| Plicamycin | 1 | 2007 | 13 | 0.080 |
Why?
|
| Animals | 10 | 2023 | 168757 | 0.070 |
Why?
|
| Lithium Chloride | 1 | 2007 | 87 | 0.070 |
Why?
|
| Receptors, Estrogen | 2 | 2007 | 2187 | 0.070 |
Why?
|
| Mutation, Missense | 1 | 2016 | 2564 | 0.070 |
Why?
|
| Culture Media, Serum-Free | 1 | 2006 | 158 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2023 | 3752 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2007 | 365 | 0.070 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2010 | 581 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2007 | 2503 | 0.070 |
Why?
|
| Infant | 2 | 2020 | 35136 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2021 | 35421 | 0.070 |
Why?
|
| Transfection | 2 | 2006 | 5892 | 0.070 |
Why?
|
| Protein Biosynthesis | 1 | 2013 | 2126 | 0.070 |
Why?
|
| Cell Line, Transformed | 1 | 2006 | 898 | 0.060 |
Why?
|
| Macrophages | 1 | 2020 | 5655 | 0.060 |
Why?
|
| Base Sequence | 1 | 2016 | 12797 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2007 | 5172 | 0.060 |
Why?
|
| Disease Progression | 1 | 2021 | 13284 | 0.060 |
Why?
|
| Cell Line | 2 | 2010 | 15997 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2007 | 705 | 0.060 |
Why?
|
| Caspase 3 | 1 | 2006 | 758 | 0.060 |
Why?
|
| Caspases | 1 | 2007 | 928 | 0.060 |
Why?
|
| Aged | 3 | 2021 | 163280 | 0.060 |
Why?
|
| Female | 7 | 2022 | 380194 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2023 | 16689 | 0.060 |
Why?
|
| NAD | 1 | 2007 | 593 | 0.060 |
Why?
|
| Peptides | 2 | 2013 | 4409 | 0.060 |
Why?
|
| Mice | 5 | 2023 | 81183 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2000 | 6364 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2010 | 1990 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2006 | 1899 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2021 | 2938 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 3129 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2007 | 2025 | 0.050 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2023 | 390 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2007 | 1640 | 0.050 |
Why?
|
| Neuroprotective Agents | 1 | 2007 | 941 | 0.050 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 3586 | 0.050 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2002 | 563 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2023 | 10481 | 0.040 |
Why?
|
| G1 Phase | 1 | 2000 | 415 | 0.040 |
Why?
|
| Drosophila melanogaster | 1 | 2007 | 1708 | 0.040 |
Why?
|
| Caenorhabditis elegans | 1 | 2007 | 1419 | 0.040 |
Why?
|
| Morpholines | 1 | 2021 | 571 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2020 | 41006 | 0.040 |
Why?
|
| Dura Mater | 1 | 2018 | 291 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2022 | 77449 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 57776 | 0.030 |
Why?
|
| Protein Binding | 1 | 2008 | 9386 | 0.030 |
Why?
|
| Adolescent | 2 | 2022 | 85781 | 0.030 |
Why?
|
| Proteins | 1 | 2010 | 6103 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2022 | 1357 | 0.030 |
Why?
|
| Cell Division | 1 | 2002 | 4568 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 1660 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2010 | 19229 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2022 | 2012 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2021 | 1526 | 0.030 |
Why?
|
| Young Adult | 1 | 2020 | 56430 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2002 | 2440 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2000 | 3846 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 3772 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 2183 | 0.030 |
Why?
|
| Child | 1 | 2020 | 77709 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2021 | 4204 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2002 | 8436 | 0.020 |
Why?
|
| DNA Helicases | 1 | 2015 | 859 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2002 | 4554 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2023 | 4445 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2002 | 13033 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2023 | 8428 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2007 | 1959 | 0.010 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2007 | 852 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2007 | 1613 | 0.010 |
Why?
|
| Longevity | 1 | 2007 | 1070 | 0.010 |
Why?
|
| Aging | 1 | 2007 | 8664 | 0.000 |
Why?
|
| Transcription Factors | 1 | 2007 | 12208 | 0.000 |
Why?
|